4. Clinical benefit table: Artz versus placebo. Dichotomous outcome measures.

Study	Time	Treatment	Outcome	No. improved	No. of pts	Risk (%)	Risk difference	NNT
Lohmander 1996	1‐4 wk	E: Artzal	Number of patients improved	59	96	61	1	100
		C: Saline		56	93	60
Shichikawa 1983a	1‐4 wk	E: Artz	Number of patients improved	87	103	84	20	5
		C: Vehicle		67	105	64
Shichikawa 1983b	1‐4 wk	E: Artz	Number of patients improved	38	48	79	9	11
		C: Vehicle		35	50	70
Lohmander 1996	5‐13 wk	E: Artzal	Number of patients improved	53	96	55	0	0
		C: Saline		51	93	55
Puhl 1993	5‐13 wk	E: Artz	Number of patients improved	86	95	91	10	10
		C: Vehicle		81	100	81
Lohmander 1996	14‐26 wk	E: Artzal	Number of patients improved	58	96	60	14	7.1
		C: Saline		43	93	46
Karlsson 2002a	14‐26 wk	E: Artzal	Number of clinical failures	2	90	2	‐9	11
		C: Saline		7	66	11
Karlsson 2002a	45‐52 wk	E: Artzal	Number of clinical failures	26	66	39	‐15	6.7
		C: Saline		26	48	54
Karlsson 2002a	14‐26 wk	E: Artzal	Number of survivors	39	90	43	10	10
		C: Saline		22	66	33